Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia
{{output}}
Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we admin... ...
